Literature DB >> 28182029

Very severe spinal muscular atrophy (Type 0).

Suleiman Al Dakhoul1.   

Abstract

This case report describes a rare phenotype of very severe spinal muscular atrophy (SMA) in a newborn who presented with reduced fetal movements in utero and significant respiratory distress at birth. The patient was homozygously deleted for exon 7 and exon 8 of the survival motor neuron gene 1. Very severe SMA should be considered in the differential diagnosis of respiratory distress at birth, and more research should be dedicated to investigate the genetic determinants of its widely variable phenotypes.

Entities:  

Keywords:  Exon; neurodegenerative; newborn; severe; spinal muscular atrophy

Year:  2017        PMID: 28182029      PMCID: PMC5255980          DOI: 10.4103/2231-0770.197512

Source DB:  PubMed          Journal:  Avicenna J Med        ISSN: 2231-0770


INTRODUCTION

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by progressive symmetrical muscle weakness resulting from the degeneration and loss of anterior horn cells in the spinal cord and brain stem nuclei. It is the most common genetic cause of infant mortality, affecting approximately 1 in 10,000 live births.[1] The disease is conventionally classified into four phenotypes [Table 1].[2]
Table 1

Phenotypes of spinal muscular atrophy

Phenotypes of spinal muscular atrophy In 1999, MacLeod et al. have described five cases of very severe SMA Type 1, all of whom presented with reduced fetal movements in utero, severe weakness at birth, and short survival time.[3]

CASE REPORT

This male newborn was the second child of unrelated parents. He was born by spontaneous vaginal delivery at 38 + 0 weeks of gestation weighing 2620 g. Antenatally, the mother, noticed reduced fetal movements in the last 2 weeks of gestation, and there was polyhydramnios on antenatal scans. She is a nonsmoker and denies any alcohol or drugs consumption. Around delivery, a mixture of nitrous oxide and oxygen (Entonox®) was used for pain relief during labor. The baby was born cyanotic, floppy with no respiratory effort and no chest wall movement. After two cycles of assisted breaths, the patient remained bradycardic with heart rate <20/min and therefore, chest compressions were initiated. The patient was intubated with size - 3.5 tube which resulted in an improvement in his oxygenation and circulatory response. On day 9 of age, examination by neurologist revealed a generalized hypotonia with absent gag and suck reflexes. Contractures of the shoulders, elbows, hips, and knees were noted. Deep tendon reflexes and jaw jerk were absent. A chest X-ray showed a right upper lobe consolidation, likely to be due to aspiration. Baby was covered with broad spectrum antibiotics: Benzylpenicillin (50 mg/kg twice daily) and gentamicin (5 mg/kg every 36 h) then vancomycin (15 mg/kg every 8 h) and ceftazidime (25 mg/kg twice daily). Cranial ultrasound showed the normal appearance of brain and ventricles with no signs of hemorrhage. A metabolic screen of amino acids and acylcarnitine was unremarkable. In genetic studies, myotonic dystrophy Type 1 was negative but the baby was homozygously deleted for exon 7 and exon 8 of survival motor neuron gene 1 (SMN1). The diagnosis was fully explained to parents and on day 12 of life, the baby was discharged to the local hospice for compassionate extubation after which he passed away.

DISCUSSION

SMA is caused by homozygous deletions or mutations in the SMN1 gene on chromosome 5 q13.[4] SMN1 exon 7 is homozygously absent in approximately 94% of patients with clinically typical SMA.[5] There is a marked correlation between SMN-encoded protein levels and disease severity in SMA.[6] In all SMA Type 0 cases reported by MacLeod and her team, centromeric SMN gene was present but in reduced copy number compared with a control group of children with the less severe Type 1 SMA.[3] Although in this case, SMA has been confirmed, polyhydramnios, to some extent, might have contributed to the clinical features and presentation. Cessation of fetal movements associated with polyhydramnios has been reported in the medical literature.[7] A review showed that, in polyhydramnios, there is a 2–5-fold increase in the risk of perinatal mortality.[8] Patients with SMA and their families or carers should be routinely offered genetic counseling. Being an autosomal recessive disease indicates that there is a 25% chance to have an affected child if both parents were found to be carriers. In an American study, Caucasians have the highest carrier's frequency and detection rate whereas African Americans had the lowest.[9]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  8 in total

1.  Prenatal onset spinal muscular atrophy.

Authors:  M J MacLeod; J E Taylor; P W Lunt; C G Mathew; S A Robb
Journal:  Eur J Paediatr Neurol       Date:  1999       Impact factor: 3.140

2.  Correlation between severity and SMN protein level in spinal muscular atrophy.

Authors:  S Lefebvre; P Burlet; Q Liu; S Bertrandy; O Clermont; A Munnich; G Dreyfuss; J Melki
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

Review 3.  A review of idiopathic hydramnios and pregnancy outcomes.

Authors:  Everett F Magann; Suneet P Chauhan; Dorota A Doherty; Monica A Lutgendorf; Marcia I Magann; John C Morrison
Journal:  Obstet Gynecol Surv       Date:  2007-12       Impact factor: 2.347

Review 4.  Spinal muscular atrophy: present state.

Authors:  H Schmalbruch; G Haase
Journal:  Brain Pathol       Date:  2001-04       Impact factor: 6.508

5.  Decreased fetal movements and polyhydramnios.

Authors:  E Sadovsky; M Perlman
Journal:  Acta Obstet Gynecol Scand       Date:  1978       Impact factor: 3.636

Review 6.  Genetic testing and risk assessment for spinal muscular atrophy (SMA).

Authors:  Shuji Ogino; Robert B Wilson
Journal:  Hum Genet       Date:  2002-10-03       Impact factor: 4.132

Review 7.  Childhood spinal muscular atrophy: controversies and challenges.

Authors:  Eugenio Mercuri; Enrico Bertini; Susan T Iannaccone
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

8.  Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens.

Authors:  Elaine A Sugarman; Narasimhan Nagan; Hui Zhu; Viatcheslav R Akmaev; Zhaoqing Zhou; Elizabeth M Rohlfs; Kerry Flynn; Brant C Hendrickson; Thomas Scholl; Deborah Alexa Sirko-Osadsa; Bernice A Allitto
Journal:  Eur J Hum Genet       Date:  2011-08-03       Impact factor: 4.246

  8 in total
  2 in total

1.  Fetal Gene Therapy Using a Single Injection of Recombinant AAV9 Rescued SMA Phenotype in Mice.

Authors:  Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Cumhur Gündüz; Hüseyin Onay; Ayça Aykut; Burak Durmaz; Meral Baka; Qin Su; Guangping Gao; Ferda Özkınay
Journal:  Mol Ther       Date:  2019-08-31       Impact factor: 11.454

2.  Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy.

Authors:  Giovanni Baranello; Ksenija Gorni; Monica Daigl; Anna Kotzeva; Rachel Evans; Neil Hawkins; David A Scott; Anadi Mahajan; Francesco Muntoni; Laurent Servais
Journal:  Clin Pharmacol Ther       Date:  2021-06-05       Impact factor: 6.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.